UroToday - The Global Online Community of Urologists urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
JAVELIN Bladder 100 Trial Interviews with Experts at Conferences
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos April 23, 2021 November 17, 2020 November 16, 2020 October 14, 2020
Conference Coverage
Conference Highlights from Recent Conference Coverage
Petros Grivas, MD, PhD
In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More
Yohann Loriot, MD, PhD
Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 tri
Testicular, Penile, and Rare GU Malignancies Interviews with Experts at Conferences
Curated by clinicians: educational forums with videos, abstracts and conference information
Videos April 27, 2021
The State-of-the-Evidence in Brief Reviews by Experts
May 17, 2021
Penile cancer (PC) is a rare malignancy with an incidence estimated less than 1/100 000 per year in the Western World
1-3
Historically, demolitive surgical approaches, such as total or partial penile amputation, were the most commonly used. Indeed, demolitive options were deemed to be necessary in order to respect a macroscopic surgical margin of at least 2 cm.
3-4 If the oncological outcomes of these approaches demonstrated to be satisfactory, they significantly affected aesthetic outcomes, as well as sexual and urinary functions.
EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer
(UroToday.com) In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer.
He began highlighting muscle invasive bladder cancer (MIBC) as a model for clinical research based on high rates of relapse and mortality following surgical intervention alone, the relatively poor use of neoadjuvant chemotherapy in spite of international guidelines, the poor prognosis of patients with residual MIBC following neoadjuvant chemotherapy, and the uncertainty of treatment approaches in patients who are ineligible for cisplatin.